Together, these results suggest that rcIL-15 exerts dual effects on tumor progression: it reduces pro-angiogenic signaling by inhibiting VEGF elevation and simultaneously boosts antitumor immune responses through IFN-γ stimulation. This evidence concerns the gene VEGFA and neoplasm.